



[Handwritten signature]

Docket No.: 13907-00006-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Dirk Vetter et al.

Application No.: 10/574,213 ✓

Confirmation No.: N/A

Filed: March 31, 2006

Art Unit: N/A

For: PROTEIN-PROTEOPHORE COMPLEXES

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Official Action on the merits as far as is known to the undersigned (37 C.F.R. 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean a search has been made or that no other material information as

defined in 37 C.F.R. 1.56(a) exists. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 13907-00006-US.

Dated:

Respectfully submitted,

By Christine Hansen

Christine M. Hansen

Registration No.: 40,634

CONNOLLY BOVE LODGE & HUTZ LLP

1007 North Orange Street

P.O. Box 2207

Wilmington, Delaware 19899

(302) 658-9141

(302) 658-5614 (Fax)

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/574,213
				Filing Date	March 31, 2006
				First Named Inventor	Dirk Vetter
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	13907-00006-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,507,466	03-26-1985	Tomalia et al.	
	AB*	US-5,519,142	05-21-1996	Hoess et al.	
	AC*	US-5,643,575	07-01-1997	Martinez et al.	
	AD*	US-5,714,166	02-03-1998	Tomalia et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-A-0-618-192 A1	10-05-1994	Hoess et al.		See AB
	BB	WO-88/01180	02-25-1988	Dow Chemical Co.		
	BC	WO-95/24221 A1	09-14-1995	Dow Chemical Co.		
	BD	WO-96/31231 A1	10-10-1996	Elan Corp. PLC		
	BE	WO-99/30727 A1	06-24-1999	Enzon Inc.		
	BF	WO-01/07469 A2	02-01-2001	Antonio Verdini		
	BG	WO-01/21197 A1	03-29-2001	U. of Utah Research Fdn.		
	BH	WO-03/030829 A2	04-17-2003	Aradigm Corp.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	JANSEN, J.F.G.A. et al., Encapsulation of Guest Molecules into a Dextritic Box, Science, American Association for the Advancement of Science, US, vol. 266, no. 5188, 8 November 1994, p. 1226-29.	
	CB	HARRIS et al., Effects of Pegylation on Pharmaceuticals, Nature (March 2003) vol. 2, p. 214-221	
	CC	TRACY, M. A., Development and Scale-up of a Microsphere Protein Delivery System, Biotechnol. Prog., American Chemical Society and American Institute of Chemical Engineers January 16, 1998, vol. 14 p. 108-115	
	CD	HERMANSON, G.T. Bioconjugate Techniques, Academic Press San Diego, USA 1996 (Table of Contents p. vii-xx)	
	CE	LEE, S. et al., Drug Delivery Systems Employing 1,6 Elimination: Releaseable Poly(ethylene glycol) Conjugates of Proteins, Bioconjugate Chem., American Chemical Society, Vol. 12 (2001) p 163-69	
	CF	VOGTLE, FRITZ ed., Dendrimers II: Architecture, Nanostructure and Supramolecular Chemistry, Springer Verlag 2000 (Table of Contents)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

476485 1.DOC



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/574,213

Attorney Docket No.: 13907-00006-US

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 24, 2006
Date


Signature

Wendy Ketcham

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (SB08)
Supplemental Information Disclosure Statement (IDS)
Return Postcard
Copies of References (14 References)